Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2017 | Pages:
120 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Influenzavirus B Infections - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenzavirus B Infections - Pipeline Review, H2 2017, provides an overview of the Influenzavirus B Infections (Infectious Disease) pipeline landscape. Type B influenza is a subtype of the influenza virus that tends to occur sporadically. Symptoms include runny nose, sore throat, aching muscles, malaise, watery eyes, aching body, loss of appetite and weakness. Treatment includes antiviral, analgesics and antipyretics medications. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenzavirus B Infections - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Influenzavirus B Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Influenzavirus B Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenzavirus B Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 15, 2, 3, 9 and 4 respectively. Similarly, the Universities portfolio in Phase III, Phase II and Discovery stages comprises 2, 1 and 2 molecules, respectively. Influenzavirus B Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Influenzavirus B Infections (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Influenzavirus B Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Influenzavirus B Infections (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Influenzavirus B Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Influenzavirus B Infections (Infectious Disease) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Influenzavirus B Infections (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Influenzavirus B Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Influenzavirus B Infections - Overview Influenzavirus B Infections - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Influenzavirus B Infections - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Influenzavirus B Infections - Companies Involved in Therapeutics Development AbbVie Inc Adimmune Corp Altravax Inc Amarillo Biosciences Inc Aphios Corp BioCryst Pharmaceuticals Inc Cadila Healthcare Ltd ContraFect Corp Daiichi Sankyo Company Ltd Fujifilm Holdings Corporation GlaxoSmithKline Plc Green Cross Corp Inovio Pharmaceuticals Inc Kineta Inc Medicago Inc MedImmune LLC Mucosis BV Novavax Inc Park Active Molecules Romark Laboratories LC Sanofi Sanofi Pasteur SA Shionogi & Co Ltd SK Chemicals Co Ltd TSRL Inc Vaxart Inc Vectura Group Plc Influenzavirus B Infections - Drug Profiles AL-18 - Drug Profile Product Description Mechanism Of Action R&D Progress APP-0205 - Drug Profile Product Description Mechanism Of Action R&D Progress APP-309 - Drug Profile Product Description Mechanism Of Action R&D Progress CF-403 - Drug Profile Product Description Mechanism Of Action R&D Progress CF-404 - Drug Profile Product Description Mechanism Of Action R&D Progress favipiravir - Drug Profile Product Description Mechanism Of Action R&D Progress Fluad (quadrivalent) - Drug Profile Product Description Mechanism Of Action R&D Progress GC-3106A - Drug Profile Product Description Mechanism Of Action R&D Progress Gene Therapy for Influenzavirus B Infections - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [serotype B] vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [serotypes A, B] (virus like particle) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strains A/H1N1 + A/H3N2 + B/victoria+ B/yamagata] (quadrivalent, split virion) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent, virus like particle) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strains A/H1N1 + A/H3N2 + B] (split virion) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strains A/H1N1 + A/H3N2 + B] vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress interferon alfa - Drug Profile Product Description Mechanism Of Action R&D Progress KIN-1400 - Drug Profile Product Description Mechanism Of Action R&D Progress laninamivir - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibodies to Inhibit Hemagglutinin for Influenza A and B Virus Infections - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibody for Influenza B Infections - Drug Profile Product Description Mechanism Of Action R&D Progress NBP-607 - Drug Profile Product Description Mechanism Of Action R&D Progress nitazoxanide CR - Drug Profile Product Description Mechanism Of Action R&D Progress PAM-1 - Drug Profile Product Description Mechanism Of Action R&D Progress peramivir - Drug Profile Product Description Mechanism Of Action R&D Progress S-033188 - Drug Profile Product Description Mechanism Of Action R&D Progress VR-736 - Drug Profile Product Description Mechanism Of Action R&D Progress VXABYW-10 - Drug Profile Product Description Mechanism Of Action R&D Progress zanamivir - Drug Profile Product Description Mechanism Of Action R&D Progress zanamivir - Drug Profile Product Description Mechanism Of Action R&D Progress Influenzavirus B Infections - Dormant Projects Influenzavirus B Infections - Discontinued Products Influenzavirus B Infections - Product Development Milestones Featured News & Press Releases Jul 24, 2017: Shionogi Announces Positive Top-Line Results for S-033188 Phase 3 Study (CAPSTONE-1) in Otherwise Healthy Influenza Patients Jun 20, 2017: Sanofi Pasteur receives MFDS Approval for VaxigripTetra inj., a New Four-Strain Influenza Vaccine Mar 06, 2017: TSRL Awarded NIH Grant to Develop Microneedle Patch for Treatment of Influenza Dec 01, 2016: Secondary Endpoint Data for S-033188, a Novel Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza, Support Favorable Primary Endpoint Data Previously Released Aug 29, 2016: Seqirus receives FDA approval for AFLURIA QUADRIVALENT (Influenza Vaccine) for people 18 years of age and older Aug 29, 2016: Shionogi Presents Results from a Phase 2 Proof-of-Concept Clinical Trial and Non-Clinical Studies of S-033188, a Novel Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza Aug 26, 2016: Daiichi Sankyo Receives Additional Dosage Regimen Approval in Japan for Long-acting Neuraminidase Inhibitor Inavir Dry Powder Inhaler 20mg Aug 25, 2016: VALNEVA Announces Signing of Marketing & Distribution Agreement for Seqirus' Flu vaccine Fluad in Austria Jun 23, 2016: New Four-Strain Influenza Vaccine, VaxigripTetra, regulatory dossier from Sanofi Pasteur now approved in Europe Jun 23, 2016: AstraZeneca provides update on Flumist Quadrivalent Vaccine in the US for the 2016-17 influenza season Feb 12, 2016: Protein Sciences and UNIGEN Reach Agreement to Source Flublok Influenza Vaccine from Japan Dec 17, 2015: Vaxart Announces Enrollment of First Patient in Influenza B Phase 1 Trial Jun 04, 2015: Kineta's Novel Broad Spectrum Antivirals Trigger Effective Natural Immune Response to Flu and Respiratory Virus Infections May 12, 2015: Kineta Presents Data On Novel Antiviral Compounds Which Inhibit Broad Spectrum of Respiratory Diseases At International Antiviral Conference Nov 03, 2014: Sanofi Pasteur Announces FDA Approval of Updated Prescribing Information for Fluzone High-Dose Vaccine for Adults 65 and Older Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Influenzavirus B Infections, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Influenzavirus B Infections - Pipeline by AbbVie Inc, H2 2017 Influenzavirus B Infections - Pipeline by Adimmune Corp, H2 2017 Influenzavirus B Infections - Pipeline by Altravax Inc, H2 2017 Influenzavirus B Infections - Pipeline by Amarillo Biosciences Inc, H2 2017 Influenzavirus B Infections - Pipeline by Aphios Corp, H2 2017 Influenzavirus B Infections - Pipeline by BioCryst Pharmaceuticals Inc, H2 2017 Influenzavirus B Infections - Pipeline by Cadila Healthcare Ltd, H2 2017 Influenzavirus B Infections - Pipeline by ContraFect Corp, H2 2017 Influenzavirus B Infections - Pipeline by Daiichi Sankyo Company Ltd, H2 2017 Influenzavirus B Infections - Pipeline by Fujifilm Holdings Corporation, H2 2017 Influenzavirus B Infections - Pipeline by GlaxoSmithKline Plc, H2 2017 Influenzavirus B Infections - Pipeline by Green Cross Corp, H2 2017 Influenzavirus B Infections - Pipeline by Inovio Pharmaceuticals Inc, H2 2017 Influenzavirus B Infections - Pipeline by Kineta Inc, H2 2017 Influenzavirus B Infections - Pipeline by Medicago Inc, H2 2017 Influenzavirus B Infections - Pipeline by MedImmune LLC, H2 2017 Influenzavirus B Infections - Pipeline by Mucosis BV, H2 2017 Influenzavirus B Infections - Pipeline by Novavax Inc, H2 2017 Influenzavirus B Infections - Pipeline by Park Active Molecules, H2 2017 Influenzavirus B Infections - Pipeline by Romark Laboratories LC, H2 2017 Influenzavirus B Infections - Pipeline by Sanofi, H2 2017 Influenzavirus B Infections - Pipeline by Sanofi Pasteur SA, H2 2017 Influenzavirus B Infections - Pipeline by Shionogi & Co Ltd, H2 2017 Influenzavirus B Infections - Pipeline by SK Chemicals Co Ltd, H2 2017 Influenzavirus B Infections - Pipeline by TSRL Inc, H2 2017 Influenzavirus B Infections - Pipeline by Vaxart Inc, H2 2017 Influenzavirus B Infections - Pipeline by Vectura Group Plc, H2 2017 Influenzavirus B Infections - Dormant Projects, H2 2017 Influenzavirus B Infections - Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
